Combinations of urine-based tumour markers in bladder cancer surveillance

References

• Brown FM. Urine cytology. Is it still the gold standard for screening? Urol Clin North Am 2000;27:25–37.
   PubMed Web of Science ®Google Scholar
• Stenzl A, Hennenlotter J, Schilling D. Can we still afford bladder cancer? Curr Opin Urol 2008;18:488–92.
   PubMed Web of Science ®Google Scholar
• Grossman HB, Stenzl A, Moyad MA, Droller MJ. Bladder cancer: chemoprevention, complementary approaches and budgetary considerations. Scand J Urol Nephrol 2008;42(Suppl):213–33.
   PubMedGoogle Scholar
• Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303–14.
   PubMed Web of Science ®Google Scholar
• Talwar R, Sinha T, Karan SC, Doddamani D, Sandhu A, Sethi GS, Voided urinary cytology in bladder cancer: is it time to review the indications? Urology 2007;70:267–71.
   PubMed Web of Science ®Google Scholar
• Feil G, Stenzl A. Tumor marker tests in bladder cancer. Actas Urol Esp 2006;30:38–45.
   PubMedGoogle Scholar
• Black PC, Brown GA, Dinney CP. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol 2006;24:5528–35.
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP III, Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005;66:35–63.
   PubMed Web of Science ®Google Scholar
• Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61:109–18.
   PubMed Web of Science ®Google Scholar
• Campos-Fernandes JL, Descotes F, Andre J, Perrin P, Devonec M, Ruffion F. Value of urinary markers in the diagnosis and follow-up of urothelial bladder tumours. Prog Urol 2007;17:23–34.
   PubMed Web of Science ®Google Scholar
• Birkhahn M, Mitra AP, Cote RJ. Molecular markers for bladder cancer: the road to a multimarker approach. Expert Rev Anticancer Ther 2007;7:1717–27.
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005;47:736–48.
   PubMed Web of Science ®Google Scholar
• Zwarthoff EC. Detection of tumours of the urinary tract in voided urine. Scand J Urol Nephrol 2008;42(Suppl):147–53.
   Google Scholar
• Drapier E, Renaudin K, Maillet F, Braud G, Laboisse C, Bouchot O. Value of the uCyt+ test for the detection and followup of bladder tumors. Prog Urol 2003;13:222–6.
   PubMedGoogle Scholar
• Mansoor I, Calam RR, Al-Khafaji B. Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma. Anal Quant Cytol Histol 2008;30:25–32.
   PubMedGoogle Scholar
• Gudjonsson S, Isfoss BL, Hansson K, Domanski AM, Warenholt J, Soller W, The value of the UroVysion® assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 2008;54:402–8.
   PubMed Web of Science ®Google Scholar
• Lekili M, Sener E, Demir MA, Temeltas G, Muezzinoglu T, Buyuksu C. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder. Urol Res 2004;32:124–8.
   PubMed Web of Science ®Google Scholar
• Kumar A, Kumar R, Gupta NP. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol 2006;36:172–5.
   PubMed Web of Science ®Google Scholar
• Feil G, Zumbragel A, Paulgen-Nelde HJ, Hennenlotter J, Maurer S, Krause S, Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder. Anticancer Res 2003;23:963–7.
   PubMed Web of Science ®Google Scholar
• Toma MI, Friedrich MG, Hautmann SH, Jakel KT, Erbersdobler A, Hellstern A, Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol 2004;22:145–9.
   PubMed Web of Science ®Google Scholar
• Friedrich MG, Toma MI, Hellstern A, Pantel K, Weisenberger DJ, Noldus J, Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int 2003;92:911–4.
   PubMed Web of Science ®Google Scholar
• Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008;26:646–51.
   PubMed Web of Science ®Google Scholar
• Gupta NP, Sharma N, Kumar R. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder. Urology 2009;73:592–6.
   PubMed Web of Science ®Google Scholar
• Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009;27:295–300.
   PubMed Web of Science ®Google Scholar